Sanara MedTech Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
SMTI$32.10+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash | $15,878,295 | $5,147,216 |
| Accounts receivable, net | 12,408,819 | 8,474,965 |
| Accounts receivable – related parties | 40,566 | 8,400 |
| Royalty receivable | - | 49,344 |
| Inventory, net | 2,753,032 | 4,717,533 |
| Convertible loan receivable | 1,101,478 | - |
| Prepaid and other assets | 1,123,798 | 608,411 |
| Total current assets | 33,305,988 | 19,005,869 |
| Long-term assets | ||
| Intangible assets, net | 41,006,776 | 44,926,061 |
| Goodwill | 3,601,781 | 3,601,781 |
| Investment in equity securities | 8,297,223 | 3,084,278 |
| Right of use assets – operating leases | 1,447,907 | 1,995,204 |
| Property and equipment, net | 432,317 | 1,257,956 |
| Total long-term assets | 54,786,004 | 54,865,280 |
| Total assets | $88,091,992 | $73,871,149 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $1,499,764 | $1,924,082 |
| Accounts payable – related parties | 30,913 | 77,805 |
| Accrued bonuses and commissions | 10,778,840 | 7,676,770 |
| Accrued royalties and expenses | 2,621,867 | 2,047,678 |
| Earnout liabilities – current | - | 1,100,000 |
| Current portion of debt | - | 580,357 |
| Operating lease liabilities – current | 358,687 | 361,185 |
| Total current liabilities | 15,290,071 | 13,767,877 |
| Long-term liabilities | ||
| Long-term debt, net of current portion | 30,689,290 | 9,113,123 |
| Earnout liabilities – long-term | 748,001 | 2,723,001 |
| Operating lease liabilities – long-term | 1,237,051 | 1,737,445 |
| Other long-term liabilities | 1,215,617 | 1,941,686 |
| Total long-term liabilities | 33,889,959 | 15,515,255 |
| Total liabilities | 49,180,030 | 29,283,132 |
| Commitments and contingencies (Note 9) | - | - |
| Shareholders’ equity | ||
| Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,753,773 issued and outstanding as of December 31, 2024 and 8,535,239 issued and outstanding as of December 31, 2023 | 8,754 | 8,535 |
| Additional paid-in capital | 77,179,211 | 72,860,556 |
| Accumulated deficit | (37,784,392) | (28,036,814) |
| Total Sanara MedTech shareholders’ equity | 39,403,573 | 44,832,277 |
| Equity attributable to noncontrolling interest | (491,611) | (244,260) |
| Total shareholders’ equity | 38,911,962 | 44,588,017 |
| Total liabilities and shareholders’ equity | $88,091,992 | $73,871,149 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.